Defined Contribution Account Manager Nova 401(k) Associates
|
TPA Retirement Plan Consultant EPIC RPS (TPA/DPS)
|
New York City District Council of Carpenters Benefit Funds
|
Fringe Benefit Group
|
Greenline Wealth Management
|
Pollard & Associates
|
Defined Contributions Compliance Consultant Loren D. Stark Company (LDSCO)
|
Defined Benefit Consultant/Enrolled Actuary Pension Plan Specialists, PC
|
Retirement Solutions Specialists
|
Senior Specialist 401k Recordkeeping T Bank N.A.
|
Great Lakes Pension Associates, Inc.
|
Defined Benefit Combo Cash Balance Compliance Consultant Loren D. Stark Company (LDSCO)
|
Retirement Planners and Administrators (RPA)
|
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
R&D Costs for Pharmaceutical Companies Do Not Explain Elevated U.S. Drug Prices
Health Affairs Mar. 7, 2017 "[T]he premiums pharmaceutical companies earn from charging substantially higher prices for their medications in the US compared to other Western countries generates substantially more than the companies spend globally on their research and development. This finding counters the claim that the higher prices paid by US patients and taxpayers are necessary to fund research and development. Rather, there are billions of dollars left over even after worldwide research budgets are covered." |
Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |